要旨

本稿は連載『妊娠高血圧症候群 診療アップデート』（全 4 回）の最終回。第 1〜3 回を通じて診療の重心がどう動いたかを振り返り、連載全体の引用文献を一望できる統合リファレンスとしてまとめる。三回を貫く一本の線は、診療の重心が「いま軽症か重症か」という静的な見方から、「いつ」を軸とする時間軸へ移ったこと――いつ予防を始め、いつ・どこまで降圧し、どの集団をいつ分娩させ、産後をどう追うか。介入は時期と集団を選んで使う。そして本連載が指し示した次の問い＝不育症（抗リン脂質抗体症候群・遺伝性血栓性素因・甲状腺自己抗体）へ橋を渡す。

本論の要点

記事本文（数値解析・原典精読・国内実装の論点）は theLetter「産科の羅針盤」で全文無料で配信しています。本ページは連載全体の総括と、引用文献の統合リファレンスを担います。各回の図表アーカイブは 第1回・第2回・第3回 の各ページに収載しています。

連載の総括 ― 「重症度」から「時間軸」へ

  1. 第1回（病態・予測・予防） ― PE は胎盤が主役の早発型と母体側が主役の晩発型を含み、ISSHP 2021 は進行中の妊娠の「軽症・重症」二分を退けた（すべての PE が重症徴候を出しうる）。予防のアスピリンを誰に始めるかは精密予測（FMF）と病歴ベース（USPSTF）の二つの入り口に分かれる。効果は全体として中等度（Henderson メタ解析 RR 0.85）だが、開始 16 週以前・1 日 100mg 以上で最も大きく早産期 PE を約 6〜7 割減らし（Roberge 2018 RR 0.33）、16 週を過ぎて始めると上乗せはほぼ失われる（RR 0.98）。
  2. 第2回（降圧・診断・急性期） ― CHAP が「降圧すると児が育たない」という半世紀の懸念を否定し、軽症慢性高血圧でも <140/90 mmHg を目標に降圧してよい方向へ国際 GL（ACOG・SMFM・NICE・ISSHP）が収束した（JSOG 2026 は軽症域を個別対応とし、ここが国際標準との分岐点）。子癇は血圧や前駆症状の軽さでは除外できず、新規の高血圧は PE と仮定して観察を強めるのが安全側。急性期は急速降圧と硫酸マグネシウムの二本柱で、日本は静注ラベタロール未承認のため静注ニカルジピンが実質の出発点。
  3. 第3回（分娩・産褥・生涯リスク） ― 計画分娩が母体に有利なのは満期（37週0日以降）の軽症 HDP（HYPITAT、帝王切開も増えない）か、後期早産期でも PE に絞った場合（PHOENIX、ただし児には NICU 入院の代償）。非重症 HDP 全体を後期早産期に即時分娩すると母体の利益は不確かなまま新生児の呼吸障害が増え（HYPITAT-II）、慢性・妊娠高血圧へ広げても母体の上乗せ利益は確認されない（WILL）。産後は介入の窓 ― 家庭血圧の自己測定＋遠隔調整で血圧関連の再入院を 27%→7%、9 か月後の左室心筋量を約 8% 低下（POPHT）。HDP の既往は分娩で終わらず、生涯の心血管リスクのマーカー。
  4. 次の問いへ ― 不育症 ― 「最新の大規模 RCT が、当然とされた介入の効き目を選り分ける」という構図は、不育症でさらに鮮明になる。APS への抗凝固、遺伝性血栓性素因への抗凝固、甲状腺自己抗体への levothyroxine ― いずれも近年の RCT が答えを更新している。次回作『不育症 ― 最新エビデンスの現在地』として、独立連載で扱う。

本文を全文無料で読む

本連載『妊娠高血圧症候群 診療アップデート』は theLetter「産科の羅針盤」で全文無料で配信しています。最終回（本稿）の総括は、下記から無料でお読みいただけます（メールアドレスのみで購読可・配信はいつでも解除できます）。

theLetter で読む（無料）

本連載 全引用文献（第1〜3回）

連載で引用した文献を、PubMed／DOI へのリンク付きで配信回ごとにまとめます。原典に直接当たるための索引としてお使いください。

第1回：病態・予測・予防

  1. Lisonkova S, et al. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013;209:544.e1-544.e12. PMID 23973398 / DOI 10.1016/j.ajog.2013.08.019
  2. Magee LA, et al. Preeclampsia〔総説〕. N Engl J Med 2022;386:1817-1832. PMID 35544388 / DOI 10.1056/NEJMra2109523
  3. Levine RJ, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683. PMID 14764923 / DOI 10.1056/NEJMoa031884
  4. Magee LA, et al. The 2021 ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2022;27:148-169. PMID 35066406 / DOI 10.1016/j.preghy.2021.09.008
  5. Houri O, et al. Phenotyping Preeclampsia Using Unsupervised Machine Learning: A Prospective Cohort Study. BJOG 2026(Epub). PMID 42136148 / DOI 10.1111/1471-0528.70262
  6. Chaiworapongsa T, et al. Preeclampsia at term: evidence of disease heterogeneity based on the profile of circulating cytokines and angiogenic factors. Am J Obstet Gynecol 2024;230:450.e1-450.e18. PMID 37806612 / DOI 10.1016/j.ajog.2023.10.002
  7. American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin No. 222. Obstet Gynecol 2020;135:e237-e260. PMID 32443079 / DOI 10.1097/AOG.0000000000003891
  8. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management（NG133）. 2019(updated 2023). https://www.nice.org.uk/guidance/ng133
  9. Society of Obstetric Medicine of Australia and New Zealand (SOMANZ). Hypertension in Pregnancy Guideline 2023〔summary: Med J Aust 2024;220:582-591. PMID 38763516〕
  10. Tan MY, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol 2018;52(2):186-195. PMID 29896812 / DOI 10.1002/uog.19112
  11. Tiruneh SA, et al. Externally validated prediction models for pre-eclampsia: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2024;63(5):592-604. PMID 37724649 / DOI 10.1002/uog.27490
  12. Foster AB, et al. Do first-trimester screening algorithms for preeclampsia aligned to use of preventative therapies reduce the prevalence of pre-term preeclampsia: A systematic review and meta-analysis. Prenat Diagn 2023;43:950-958. PMID 37277892 / DOI 10.1002/pd.6394
  13. US Preventive Services Task Force (Davidson KW, et al). Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: USPSTF Recommendation Statement. JAMA 2021;326:1186-1191. PMID 34581729 / DOI 10.1001/jama.2021.14781
  14. Henderson JT, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the USPSTF. JAMA 2021;326:1192-1206. PMID 34581730 / DOI 10.1001/jama.2021.8551
  15. Montgomery-Csobán T, et al. Machine learning-enabled maternal risk assessment for women with pre-eclampsia (the PIERS-ML model): a modelling study. Lancet Digit Health 2024;6:e238-e250. PMID 38519152 / DOI 10.1016/S2589-7500(23)00267-4
  16. Rolnik DL, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia（ASPRE）. N Engl J Med 2017;377:613-622. PMID 28657417 / DOI 10.1056/NEJMoa1704559
  17. Roberge S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017;216:110-120.e6. PMID 27640943 / DOI 10.1016/j.ajog.2016.09.076
  18. Roberge S, et al. Aspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol 2018;218:287-293.e1. PMID 29138036 / DOI 10.1016/j.ajog.2017.11.561
  19. Hu X, et al. The optimal dosage of aspirin for preventing preeclampsia in high-risk pregnant women: A network meta-analysis of 23 randomized controlled trials. J Clin Hypertens (Greenwich) 2024;26:455-464. PMID 38683867 / DOI 10.1111/jch.14821
  20. van Doorn R, et al. Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: A systematic review and meta-analysis. PLoS One 2021;16:e0247782. PMID 33690642 / DOI 10.1371/journal.pone.0247782
  21. Hoffman MK, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet 2020;395:285-293. PMID 31982074 / DOI 10.1016/S0140-6736(19)32973-3
  22. Ayala DE, et al. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013;30:260-279. PMID 23004922 / DOI 10.3109/07420528.2012.717455
  23. Hofmeyr GJ, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2018;10:CD001059. PMID 30277579 / DOI 10.1002/14651858.CD001059.pub5
  24. 医薬品医療機器総合機構（PMDA）. バイアスピリン錠100mg 添付文書（第4版、2026年1月改訂、製造販売元：バイエル薬品、承認番号 21200AMY00212000）
  25. US Food and Drug Administration (FDA). Drug Safety Communication: FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later（2020-10-15）. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later
  26. Goadsby J, et al. Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial. Lancet 2026;407:67-77(Epub 2025-12-04). PMID 41354041 / DOI 10.1016/S0140-6736(25)01207-3

第2回：降圧・診断・急性期

  1. Tita AT, et al. Treatment for Mild Chronic Hypertension during Pregnancy（CHAP）. N Engl J Med 2022;386:1781. PMID 35363951 / DOI 10.1056/NEJMoa2201295
  2. Magee LA, et al. Less-Tight versus Tight Control of Hypertension in Pregnancy（CHIPS）. N Engl J Med 2015;372:407. PMID 25629739 / DOI 10.1056/NEJMoa1404595
  3. Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018;(10):CD002252. PMID 30277556 / DOI 10.1002/14651858.CD002252.pub4
  4. Sanusi AA, Leach J, Boggess K, Dugoff L. Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension. Obstet Gynecol 2024;144(1):126-134. PMID 38949541 / DOI 10.1097/AOG.0000000000005613
  5. Webster LM, et al. Labetalol Versus Nifedipine as Antihypertensive Treatment for Chronic Hypertension in Pregnancy. Hypertension 2017;70(5):915-922. PMID 28893900 / DOI 10.1161/HYPERTENSIONAHA.117.09972
  6. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994;309(6966):1395-1400. PMID 7819845 / DOI 10.1136/bmj.309.6966.1395
  7. Altman D, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate?（The Magpie Trial）. Lancet 2002;359:1877. PMID 12057549 / DOI 10.1016/S0140-6736(02)08778-0
  8. Duley L, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010;(11):CD000025. PMID 21069663 / DOI 10.1002/14651858.CD000025.pub2
  9. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013;(7):CD001449. PMID 23900968 / DOI 10.1002/14651858.CD001449.pub3
  10. Jeyabalan A, Larkin JC. Chronic hypertension in pregnancy: Prenatal and postpartum care. UpToDate; topic last updated Apr 20, 2026
  11. Norwitz ER. Eclampsia. UpToDate; topic last updated Aug 04, 2025
  12. 〔第1回・第3回と共通〕ISSHP 2021（PMID 35066406）／ACOG PB222（PMID 32443079）／NICE NG133／JSOG 産婦人科診療ガイドライン 産科編 2026

第3回：分娩・産褥・生涯リスク

  1. Koopmans CM, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation（HYPITAT）. Lancet 2009;374(9694):979-988. PMID 19656558 / DOI 10.1016/S0140-6736(09)60736-4
  2. Broekhuijsen K, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation（HYPITAT-II）. Lancet 2015;385(9986):2492-2501. PMID 25817374 / DOI 10.1016/S0140-6736(14)61998-X
  3. Chappell LC, et al. Planned early delivery or expectant management for late preterm pre-eclampsia（PHOENIX）. Lancet 2019;394(10204):1181-1190. PMID 31472930 / DOI 10.1016/S0140-6736(19)31963-4
  4. Magee LA, et al. Determining optimal timing of birth for women with chronic or gestational hypertension at term: The WILL randomised trial. PLoS Med 2024;21(11):e1004481. PMID 39591427 / DOI 10.1371/journal.pmed.1004481
  5. Churchill D, Duley L, Thornton JG, et al. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane Database Syst Rev 2018;(10):CD003106. PMID 30289565 / DOI 10.1002/14651858.CD003106.pub3
  6. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2020;(12):CD004454. PMID 33368142 / DOI 10.1002/14651858.CD004454.pub4
  7. Beardmore-Gray A, et al. Planned early birth versus expectant management for hypertensive disorders from 34 weeks' gestation to term. Cochrane Database Syst Rev 2026;(5):CD009273. PMID 42161381 / DOI 10.1002/14651858.CD009273.pub3
  8. Beardmore-Gray A, et al. Planned delivery or expectant management in preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2022;227(2):218-230.e8. PMID 35487323 / DOI 10.1016/j.ajog.2022.04.034
  9. Duhig KE, et al. Placental growth factor testing to assess women with suspected pre-eclampsia（PARROT）. Lancet 2019;393(10183):1807-1818. PMID 30948284 / DOI 10.1016/S0140-6736(18)33212-4
  10. Mendoza M, et al. Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia（StopPRE）. JAMA 2023;329(7):542-550. PMID 36809321 / DOI 10.1001/jama.2023.0691
  11. Kitt J, et al. Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management（POP-HT）. JAMA 2023;330(20):1991-1999. PMID 37950919 / DOI 10.1001/jama.2023.21523
  12. Kitt J, et al. Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Imaging Substudy. Circulation 2024;149:529-541. PMID 37950907 / DOI 10.1161/CIRCULATIONAHA.123.067597
  13. Lovgren T, et al. Postpartum management of hypertension and effect on readmission rates. Am J Obstet Gynecol MFM 2022;4(1):100517. PMID 34757235 / DOI 10.1016/j.ajogmf.2021.100517
  14. Wang CY, et al. Rate of Postpartum Readmission for Hypertension After Prescribing Nifedipine Upon Hospital Discharge Compared With Labetalol. O&G Open 2025;2(1):e057. PMID 41000567 / DOI 10.1097/og9.0000000000000057
  15. Dall'Asta A, et al. Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms. Ultrasound Obstet Gynecol 2021;57(5):698-709. PMID 32484256 / DOI 10.1002/uog.22107
  16. Vestergaard AHS, et al. Proteinuria in Preeclampsia and Long-Term Risk of Maternal Kidney and Cardiovascular Disease. BJOG 2026. PMID 42152801 / DOI 10.1111/1471-0528.70265
  17. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3(1):1-150.
  18. Bauer ME, et al. The Society for Obstetric Anesthesia and Perinatology Interdisciplinary Consensus Statement on Neuraxial Procedures（SOAP）. Anesth Analg 2021;132(6):1531-1544. PMID 33861047 / DOI 10.1213/ANE.0000000000005355
  19. Kearns RJ, et al. Epidural analgesia during labour and severe maternal morbidity: population based study. BMJ 2024;385:e077190. PMID 38777357 / DOI 10.1136/bmj-2023-077190
  20. Anim-Somuah M, et al. Epidural versus non-epidural or no analgesia for pain management in labour. Cochrane Database Syst Rev 2018;(5):CD000331. PMID 29781504 / DOI 10.1002/14651858.CD000331.pub4
  21. Hawkins JL, McQuaid-Hanson E. Anesthesia for the patient with preeclampsia. UpToDate. ／ Norwitz ER, Funai EF. Preeclampsia with severe features: Delaying delivery. UpToDate. ／ Melvin LM, Funai EF. Gestational hypertension. UpToDate. ／ August P, Jeyabalan A. Preeclampsia: Prevention. UpToDate.
  22. 〔ガイドライン〕JCS/JSOG 2026（日本循環器学会・日本産科婦人科学会 合同ガイドライン 2026改訂）／JSOG 産婦人科診療ガイドライン 産科編 2026／MAGPIE・ACOG PB222 は第2回と共通

※ 第4回として当初予告した「抗リン脂質抗体症候群（APS）と日本での実装」は、独立連載『不育症 ― 最新エビデンスの現在地』で原典に基づき改めて扱います。